Filing Details
- Accession Number:
- 0001062993-24-014289
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-01 16:05:16
- Reporting Period:
- 2024-07-31
- Accepted Time:
- 2024-08-01 16:05:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1205922 | Vaccinex Inc. | VCNX | Pharmaceutical Preparations (2834) | 161603202 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1268239 | Albert Friedberg | 220 Bay Street Suite 600 Toronto A6 M5J 2W4 | Yes | No | Yes | No | |
1678258 | Fcmi Parent Co. | 220 Bay Street Suite 600 Toronto A6 M5J 2W4 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-07-31 | 100,629 | $5.74 | 663,044 | No | 4 | P | Indirect | By FCMI Parent Co. |
Common Stock | Acquisiton | 2024-07-31 | 83,243 | $6.41 | 746,287 | No | 4 | P | Indirect | By FCMI Parent Co. |
Common Stock | Acquisiton | 2024-07-31 | 16,128 | $7.40 | 762,415 | No | 4 | P | Indirect | By FCMI Parent Co. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By FCMI Parent Co. |
No | 4 | P | Indirect | By FCMI Parent Co. |
No | 4 | P | Indirect | By FCMI Parent Co. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 2,094 | Direct | |
Common Stock | 180 | Indirect | By Pan Atlantic Holdings Ltd. |
Common Stock | 16,724 | Indirect | By Friedberg Global-Macro Hedge Fund Ltd. |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Warrant (Right to Buy) | $7.64 | 2024-03-28 | 2029-03-28 | 102,960 | 102,960 | Indirect |
Common Stock | Warrant (Right to Buy) | $14.00 | 2024-02-08 | 2029-02-08 | 118,226 | 118,226 | Indirect |
Common Stock | Warrant (Right to Buy) | $14.00 | 2023-10-03 | 2028-10-03 | 214,285 | 214,285 | Indirect |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2029-03-28 | 102,960 | 102,960 | Indirect |
2029-02-08 | 118,226 | 118,226 | Indirect |
2028-10-03 | 214,285 | 214,285 | Indirect |
Footnotes
- Mr. Friedberg is the majority owner of Pan Atlantic Holdings Ltd. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- Mr. Friedberg possesses voting and dispositive power over the reported securities and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $6.10, inclusive. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.11 to $7.06, inclusive. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.18 to $7.40, inclusive. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.